Cookie Consent by FreePrivacyPolicy.com
Datalog Logo
Free data on 57M+ companies
Home
Company Information for

CELEX ONCOLOGY INNOVATIONS LIMITED

101 NEW CAVENDISH STREET, 1ST FLOOR SOUTH, LONDON, W1W 6XH,
Company Registration Number
11085607
Private Limited Company
Active

Company Overview

About Celex Oncology Innovations Ltd
CELEX ONCOLOGY INNOVATIONS LIMITED was founded on 2017-11-28 and has its registered office in London. The organisation's status is listed as "Active". Celex Oncology Innovations Limited is a Private Limited Company registered in UNITED KINGDOM with Companies House and the accounts submission requirement is categorised as TOTAL EXEMPTION FULL
  • Company qualifies as a small company
  • Company has filed full accounts
  • Company is exempt from audit
  • Annual turnover is less than £6.5 million
  • The balance sheet total is less than £ 3.26 million
  • Employs less than 50 employees
Key Data
Company Name
CELEX ONCOLOGY INNOVATIONS LIMITED
 
Legal Registered Office
101 NEW CAVENDISH STREET
1ST FLOOR SOUTH
LONDON
W1W 6XH
 
Filing Information
Company Number 11085607
Company ID Number 11085607
Date formed 2017-11-28
Country UNITED KINGDOM
Origin Country United Kingdom
Type Private Limited Company
CompanyStatus Active
Lastest accounts 31/12/2022
Account next due 30/09/2024
Latest return 
Return next due 26/12/2018
Type of accounts TOTAL EXEMPTION FULL
VAT Number /Sales tax ID GB333152241  
Last Datalog update: 2024-04-06 19:41:40
Primary Source:Companies House
Is this data useful to you?
If you found the data here useful, PLEASE HELP US. We are a start-up and believe in making information freely available. Please DONATE to help.
Alternatively by linking to us, posting on twitter, facebook and linkedin about us and generally spreading the word, you'll help us to grow. Our vision is to provide high quality data about the activities of all the companies in the world and where possible make it free to use and view. Finding and integrating data from thousands of data sources is time consuming and needs lots of effort. By simply spreading the word about us, you will help us.

Company Officers of CELEX ONCOLOGY INNOVATIONS LIMITED

Current Directors
Officer Role Date Appointed
LAURENCE JOHN COHEN
Director 2017-11-28
MUSTAFA BILGIN ALI DJAMGOZ
Director 2017-11-28

Related Directorships

Officer Related Company Role Date Appointed Role StatusIncorporation dateCompany Status
LAURENCE JOHN COHEN EDGE PETROL LIMITED Director 2016-12-15 CURRENT 2015-06-11 Active
MUSTAFA BILGIN ALI DJAMGOZ INAP ONCOLOGY LIMITED Director 2013-10-28 CURRENT 2013-10-28 Dissolved 2017-03-28
MUSTAFA BILGIN ALI DJAMGOZ TURKUAS-UK Director 2013-05-10 CURRENT 2013-05-10 Dissolved 2014-12-23
MUSTAFA BILGIN ALI DJAMGOZ NAVION LIMITED Director 2008-11-28 CURRENT 2008-07-11 Dissolved 2014-03-18
MUSTAFA BILGIN ALI DJAMGOZ PRO CANCER RESEARCH FUND Director 2001-10-29 CURRENT 2001-10-29 Active

More director information

Corporation Filing History
Companies House Filing History
This is a record of the public documents (corporate filing) lodged from Companies House where the company has filed annual returns and other statutory filing documents. Examples of documents filed include: change of registered office, accounts filing, director/officer appointments & resignations, changes in share capital, shareholder members lists etc.

DateDocument TypeDocument Description
2024-05-22DIRECTOR APPOINTED DR RACHED SAMI BAKRI
2024-04-0524/03/24 STATEMENT OF CAPITAL GBP 683.489338
2024-04-0524/03/24 STATEMENT OF CAPITAL GBP 722.921402
2024-04-0524/03/24 STATEMENT OF CAPITAL GBP 755.781488
2024-04-0524/03/24 STATEMENT OF CAPITAL GBP 762.353466
2024-04-0524/03/24 STATEMENT OF CAPITAL GBP 765.639504
2024-04-0524/03/24 STATEMENT OF CAPITAL GBP 768.268354
2024-04-0524/03/24 STATEMENT OF CAPITAL GBP 774.840332
2024-04-0524/03/24 STATEMENT OF CAPITAL GBP 778.12637
2024-04-0524/03/24 STATEMENT OF CAPITAL GBP 780.75522
2024-04-0524/03/24 STATEMENT OF CAPITAL GBP 783.38407
2024-04-0524/03/24 STATEMENT OF CAPITAL GBP 786.01292
2024-04-0524/03/24 STATEMENT OF CAPITAL GBP 788.64177
2024-04-0524/03/24 STATEMENT OF CAPITAL GBP 791.27062
2024-04-0524/03/24 STATEMENT OF CAPITAL GBP 793.89947
2024-04-0525/03/24 STATEMENT OF CAPITAL GBP 811.04947
2024-04-0525/03/24 STATEMENT OF CAPITAL GBP 825.74947
2024-04-0525/03/24 STATEMENT OF CAPITAL GBP 840.44947
2024-04-05CONFIRMATION STATEMENT MADE ON 05/04/24, WITH UPDATES
2024-04-0309/02/24 STATEMENT OF CAPITAL GBP 440.162786
2024-04-0309/02/24 STATEMENT OF CAPITAL GBP 459.762786
2024-04-0314/02/24 STATEMENT OF CAPITAL GBP 477.84604
2024-04-0314/02/24 STATEMENT OF CAPITAL GBP 598.401328
2024-04-0309/02/24 STATEMENT OF CAPITAL GBP 608.201328
2024-04-0319/03/24 STATEMENT OF CAPITAL GBP 637.601328
2024-04-0319/03/24 STATEMENT OF CAPITAL GBP 657.201328
2024-03-26APPOINTMENT TERMINATED, DIRECTOR MUSTAFA BILGIN ALI DJAMGOZ
2024-01-02CONFIRMATION STATEMENT MADE ON 04/12/23, WITH UPDATES
2023-04-03REGISTERED OFFICE CHANGED ON 03/04/23 FROM 64 New Cavendish Street London W1G 8TB England
2022-12-18CONFIRMATION STATEMENT MADE ON 04/12/22, WITH UPDATES
2022-09-13Sub-division of shares on 2022-08-15
2022-08-31Resolutions passed:<ul><li>Resolution Nominal value of each share be sub dividend 15/08/2022</ul>
2022-08-3115/08/22 STATEMENT OF CAPITAL GBP 0.0001
2022-08-31SH0115/08/22 STATEMENT OF CAPITAL GBP 0.0001
2022-08-31RES13Resolutions passed:
  • Nominal value of each share be sub dividend 15/08/2022
2022-05-13AA31/12/21 ACCOUNTS TOTAL EXEMPTION FULL
2021-12-07CS01CONFIRMATION STATEMENT MADE ON 04/12/21, WITH NO UPDATES
2021-11-11TM01APPOINTMENT TERMINATED, DIRECTOR AJMAL RAHMAN
2021-09-03AA31/12/20 ACCOUNTS TOTAL EXEMPTION FULL
2020-12-15CS01CONFIRMATION STATEMENT MADE ON 04/12/20, WITH UPDATES
2020-11-04MEM/ARTSARTICLES OF ASSOCIATION
2020-11-04RES01ADOPT ARTICLES 04/11/20
2020-10-26AD01REGISTERED OFFICE CHANGED ON 26/10/20 FROM 9th Floor, the Royal Liver Building Pier Head Liverpool L3 1JH United Kingdom
2020-10-08RP04SH01Second filing of capital allotment of shares GBP400
2020-09-27AA31/12/19 ACCOUNTS TOTAL EXEMPTION FULL
2020-07-04AP01DIRECTOR APPOINTED MR AJMAL RAHMAN
2020-06-26RES12Resolution of varying share rights or name
2020-06-09PSC04Change of details for Professor Mustafa Bilgin Ali Djamgoz as a person with significant control on 2020-06-08
2020-06-09TM01APPOINTMENT TERMINATED, DIRECTOR BRIAN PERCIVAL DE THORPE MILLARD
2020-06-09PSC07CESSATION OF VASILEIOS XENIADES AS A PERSON OF SIGNIFICANT CONTROL
2019-12-14CS01CONFIRMATION STATEMENT MADE ON 04/12/19, WITH UPDATES
2019-09-26AP01DIRECTOR APPOINTED MR BRIAN PERCIVAL DE THORPE MILLARD
2019-09-26SH0125/09/19 STATEMENT OF CAPITAL GBP 571.43
2019-09-26PSC01NOTIFICATION OF A PERSON WITH SIGNIFICANT CONTROL VASILEIOS XENIADES
2019-09-26PSC07CESSATION OF LAURENCE JOHN COHEN AS A PERSON OF SIGNIFICANT CONTROL
2019-09-26SH02Sub-division of shares on 2019-07-28
2019-08-19RES13Resolutions passed:
  • Auth share capital increased 28/07/2019
  • Resolution of varying share rights or name
  • Resolution of allotment of securities
  • Resolution of removal of pre-emption rights
  • ADOPT ARTICLES
2019-08-07SH0105/08/19 STATEMENT OF CAPITAL GBP 100
2019-07-24AP01DIRECTOR APPOINTED MR CARSTEN KRONSBJERG FALTUM
2019-03-19AAACCOUNTS FOR DORMANT COMPANY MADE UP TO 31/12/18
2018-12-04CS01CONFIRMATION STATEMENT MADE ON 04/12/18, WITH NO UPDATES
2018-11-29CS01CONFIRMATION STATEMENT MADE ON 27/11/18, WITH NO UPDATES
2018-02-19AA01Current accounting period extended from 30/11/18 TO 31/12/18
2018-02-13CH01Director's details changed for Professor Musfafa Bilgin Ali Djamgoz on 2017-11-28
2018-02-13PSC04Change of details for Professor Musfafa Bilgin Ali Djamgoz as a person with significant control on 2017-11-28
2017-11-28LATEST SOC28/11/17 STATEMENT OF CAPITAL;GBP 2
2017-11-28NEWINCNew incorporation
Industry Information
SIC/NAIC Codes
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
211 - Manufacture of basic pharmaceutical products
21100 - Manufacture of basic pharmaceutical products




Licences & Regulatory approval
We could not find any licences issued to CELEX ONCOLOGY INNOVATIONS LIMITED or authorisation from an industry specific regulator to operate. These may not be required.
Share this page on Facebook
Risks
Legal Notices
No legal notices or events such as winding-up orders or proposals to strike-off have been issued
Fines / Sanctions
No fines or sanctions have been issued against CELEX ONCOLOGY INNOVATIONS LIMITED
Liabilities
Mortgages / Charges
Total # Mortgages/Charges 0
Mortgages/Charges outstanding 0
Mortgages Partially Satisifed 0
Mortgages Satisfied/Paid 0
Details of Mortgagee Charges
CELEX ONCOLOGY INNOVATIONS LIMITED does not have any mortgage charges so there is no mortgagee data available

  Average Max

This shows the max and average number of mortgages for companies with the same SIC code of 21100 - Manufacture of basic pharmaceutical products

Filed Financial Reports
Annual Accounts
2018-12-31
Annual Accounts
2019-12-31
Annual Accounts
2020-12-31
Annual Accounts
2021-12-31

These are the financial reports (either an abhreviated set of accounts or profit& loss statement and balance sheet) have been filed with Companies House. The reports allow you to do a basic business credit check on CELEX ONCOLOGY INNOVATIONS LIMITED

Intangible Assets
Patents
We have not found any records of CELEX ONCOLOGY INNOVATIONS LIMITED registering or being granted any patents
Domain Names
We do not have the domain name information for CELEX ONCOLOGY INNOVATIONS LIMITED
Trademarks
We have not found any records of CELEX ONCOLOGY INNOVATIONS LIMITED registering or being granted any trademarks
Income
Government Income
We have not found government income sources for CELEX ONCOLOGY INNOVATIONS LIMITED. This could be because the transaction value was below £ 500 with local government or below £ 25,000 for central government. We have found 8,000 supplier to government that are UK companies so approx 0.2% of companies listed on Datalog supply to government.

The top companies supplying to UK government with the same SIC code (21100 - Manufacture of basic pharmaceutical products) as CELEX ONCOLOGY INNOVATIONS LIMITED are:

Outgoings
Business Rates/Property Tax
No properties were found where CELEX ONCOLOGY INNOVATIONS LIMITED is liable for the business rates / property tax. This could be for a number of reasons.
  • The council hasnt published the data
  • We havent found or been able to process the councils data
  • The company is part of a group of companies and another company in the group is liable for business rates
  • The registered office may be a residential address which does not have a commercial designation. If the business is run from home then it won't be a commercial property and hence won't be liable for business rates.
  • Serviced offices are increasingly popular and therefore a business may not be paying business rates directly - the building owner is and this is incorporated in the office rental charge.
Government Grants / Awards
Technology Strategy Board Awards
The Technology Strategy Board has not awarded CELEX ONCOLOGY INNOVATIONS LIMITED any grants or awards. Grants from the TSB are an indicator that the company is investing in new technologies or IPR
European Union CORDIS Awards
The European Union has not awarded CELEX ONCOLOGY INNOVATIONS LIMITED any grants or awards.
Ownership
    We could not find any group structure information
    Is this data useful to you?
    If you found the data here useful, PLEASE HELP US. We are a start-up and believe in making information freely available. Please DONATE to help.
    Alternatively by linking to us, posting on twitter, facebook and linkedin about us and generally spreading the word, you'll help us to grow. Our vision is to provide high quality data about the activities of all the companies in the world and where possible make it free to use and view. Finding and integrating data from thousands of data sources is time consuming and needs lots of effort. By simply spreading the word about us, you will help us.
    Need more information?
    We offer bespoke investigations into companies. If you need more information about this company we can gather more information as directed by you. This may, for example, be a forensic investigation such as tracing hidden assets. The engagement is on a time and materials basis. We charge GBP £ 500 per day + VAT. Contact us with a description of what you're looking for and we will assess whether we can help.